Connect Biopharma Strengthens Leadership By Adding Veteran Executive Jim Schoeneck To Its Board Of Directors

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory diseases, has announced the expansion of its Board of Directors from six to seven members. Along with this change, the company has appointed Jim Schoeneck as a new director, effective immediately. Jim Schoeneck brings over four decades of leadership experience in the biotech and pharmaceutical industry. Throughout his career, he has played a key role in the development and commercialization of breakthrough therapies and has successfully led several companies through major phases of growth and change, including mergers and acquisitions.

Kleanthis G. Xanthopoulos, Chairman of the Board of Directors, stated, “We are pleased to welcome Jim to our Board of Directors. His deep expertise in drug development and commercialization will make him an invaluable asset as we continue to build a proven team of industry experts to rapidly advance the development and commercialization of rademikibart.”

Barry Quart, Chief Executive Officer of Connect Biopharma mentioned, “Rademikibart has demonstrated a differentiated clinical profile that would uniquely position it to rapidly treat the millions of patients with asthma or COPD who experience an acute exacerbation annually. We look forward to leveraging Jim’s strategic and commercial acumen as we advance our Phase 2 Seabreeze STAT studies towards clinical data expected in the first half of 2026.”

Mr. Schoeneck, also added, “I am delighted to join Connect and have been impressed by the potential of rademikibart to transform the treatment paradigm for acute and chronic asthma and COPD patients. I look forward to working closely with the team to guide the Company’s development efforts and chart a course for long-term commercial success.”

He currently serves as Chairman of the Board at both FibroGen, Inc. and Calidi Biotherapeutics, Inc. In the past, he has held CEO and board positions at Depomed, Inc., BrainCells Inc., ActivX Biosciences, Inc., and Prometheus Laboratories Inc. He has also contributed to public health initiatives through his role as Chairman of the National Board of Directors for the Asthma and Allergy Foundation of America. Mr. Schoeneck began his professional journey at Rhone-Poulenc Rorer Inc. and holds a Bachelor of Science degree from Jacksonville State University.